Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effect of SGLT2 Inhibitor on Metabolic-Dysfunction-Associated Fatty Liver Disease in Patients With Insulin Resistance
Sponsor: Sherihan AboElyazed Mohamed Khalil
Summary
Metabolic-dysfunction-associated fatty liver disease (MAFLD) has evolved as a major health problem recently. Discovering ways to prevent or delay the progression of MAFLD has become a global focus. Lifestyle modifications remain the cornerstone of MAFLD treatment, even though various pharmaceutical interventions are currently under clinical trial. Among them, sodium-glucose co-transporter type-2 inhibitors (SGLT-2i) are emerging as promising agents. In this study we aim to evaluate the effect of SGLT2 inhibitors on fatty liver disease in patients with prediabetes and type 2 diabetes
Official title: Effect of SGLT2 Inhibitor on Metabolic-Dysfunction Associated Fatty Liver Disease in Patients With Insulin Resistance
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
66
Start Date
2026-10-01
Completion Date
2027-10-01
Last Updated
2026-10-23
Healthy Volunteers
No
Conditions
Interventions
Dapagliflozin 5Mg Tab
Dapagliflozin 5 mg per os once daily will be used for the prediabetic group (1)
Metfomin 500 mg
Metformin 500 mg once daily after lunch will be used for the prediabetes group (2)
Dapagliflozin (10mg Tab)
Dapagliflozin 10 mg per os once daily will be used for diabetic patients not previously receiving SGLT2
Locations (1)
Ain Shams University hospital
Cairo, Egypt